EMA Authorised: Itovebi (inavolisib) — Roche Registration GmbH

View source ↗

Summary

EMA authorised Itovebi (inavolisib) by Roche Registration GmbH for breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ITOVEBI (INAVOLISIB)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 06/01/2026